Estrogen ~ding protein activities were determined in the cytosoJirom adult male Buffalo rat liver and Morris hepatomb 7777. Estrogen receptors were prepared using the protamine sulfate precipitation technique of Chamness. The ability of various unlabeled steroids competing with eHJestradiol was examined to establish the binding specificity. Estradiol binding in Morris hepatoma 7777 cytosol was greatly decreased compared with that present in hepatic cytosol prepared from normal rat liver. The receptor concentration expressed as femtomoles per milligram of cytoplasmic protein was 31.1 ± 2.9 SD for normal rat liver and 0.41 ± 0.88 SD for the hepatoma. Gel filtration chromatography revealed the presence of an estrogen binder in hepatoma cytosol which was not present in either normal liver or in the protamine sulfate precipitates of hepatoma cytosol. The molecular weight, binding specificity. and precipitation of this protein by specific antiserum suggests that it is a-fetoprotein.
After the original discovery of estrogen receptor in the liver (5) (6) (7) (8) (9) (10) (11) (12) , many attempts have been made to define a possible role for steroid hormones; particularly estrogens, in the pathogenesis of various hepatic d.iseases. This is particularly true for diseases such as hepatic adenoma (13.14) , focal nodular hyperplasia (15) (16) (17) (18) , hepatoma, and angiosarcoma (19) (20) (21) (22) , although the relationship between estrogens and focal nodular hyperplasia has been questioned. recently (23) . Each of these hepatic disorders has been associated, at least circumstantially, with the longterm use of steroidal agents such as estrogens, androgens, or prednisone for any of a variety of clinical indications.
The present study is a report on the identification and quantitation of estrogen receptors in cytosol obtained from normal rat liver and from the Morris hepatoma 7777. The latter is a well-differentiated trabecular carcinoma (24) and was originally induced by feeding N-2-fluorenylphthalmic acid (FPA) to Buffalo strain inbred rats. It is a fast growing "minimal deviation" tumor which grows well in both sexes, although it was maintained primarily in male rats in our laboratory.
Methods

Tissue
Livers from adult male Buffalo rats were used (250 g). The animals were killed by decapitation and the livers were removed, washed, and placed immediately in iced saline solution for later processing. Morris hepatomas 7777 in Buffalo rats were transplanted subcutaneously to Buffalo recipients. The tumors were removed for the Abbreviations used in this paper: AFP. a-fetoprotein; BSA. bovine serurnalbumin; DHT. 5.a-dihydrotestosterone; DES. diethylstilbesterol; E " estrone; E2• estradiol; E3• estriol; FPA. N-2-fluorenylphthalmic acid; 2-0Me-E2 • 2-methoxyestradiol. preparation of cytosol when the tumor weight was judged to be equal to liver weight (-10 g).
Materials
Estrone (El ), estradiol (E2), estriol (E3), and 2-methoxyestradiol (2-OMe-E2), were purchased from Steraloids, Wilton, N.H. Diethylstilbesterol (DES), testosterone, 5,adihydrotestosterone (DlIT) , progesterone, bovine serum albumin (BSA), standards for gel filtration chromatography, and protamine sulfate were purchased from Sigma Chemical Company, St. Louis, Mo. Norit A and dextran C were obtained from Fisher Scientific Company, Pittsburgh, Pa. Protein A -Sepharose was obtained from Pharmacia Fine Chemicals, Piscataway, N.J.; rabbit antiserum to mouse afetoprotein and goat antiserum to rabbit IgG were purchased from Miles Laboratories, Elkhart, Ind. [2, 4, 6, 7, 16, 17 3HJEs-tradiol, [3HIEz, 151 Cilmmol, was obtained from New England Nuclear, Boston. Mass. The radiolabeled material used in these studies was assayed periodically for purity by thinlayer chromatography on silica gel G in ethyl acetatelhexanel ethanol (85:10:5), and was used only if purity as determined by radiolabel migration was 95%.
Preparation of Cytosol
Approximately 10 g of tissue was used for each assay. All procedures were performed at DOC. The liver was minced and homogenized with a Brinkmann polytron (Brinkmann Instruments, Inc., Westbury, N.Y.) in 2 volumes of TED buffer [0.01 M Tris-HCI, 1.5 mM ethylenediaminetetraacetate (EDT A), 0.01 mM dithiothreitol, pH 7.41. The resultant homogenate was centrifuged for 60 min at 105,000 g. The supernate was removed carefully to prevent lipid contamination and treated with Norit A and dextran C according to the technique of Chamness (8, 25) . The final protein concentration in the cytosol samples prepared was 15-25 mg/ml. Immediately before use, the cytosol was diluted to a final protein concentration of 5 mg/ml.
Protamine Sulfate Assay
Receptors were prepared using the protamine sulfate precipitation technique of Chamness et al. (8, 25) , which precludes contamination due to binding of steroid to the moderate-affinity high-capacity male specific estrogen binder (12) . Cytosol (0.2 ml) pretreated with dextrancoated charcoal and protamine sulfate (0.2 ml) solution (1.5 mg/ml in TED buffer) were combined in multiple replicate tubes and mixed briefly. After standing for 5 min at DoC, the reaction tubes were centrifuged at 800 g for 10 min and the supernate was removed by suction. A 250-MI aliquot of radioactive steroid solution, with or without unlabeled hormone, was then added to each tube. After incubation for 18 h at DoC, the supernate was removed and the precipitate in each tube was washed with three 2-ml aliquots of cold TED buffer. The precipitate, at the bottom of the reaction tube. was dropped in a scintillation vial 
Gel Filtration Chromatography
Gel filtration chromatography of cytosolic proteins was carried out on Sephadex G-100 in Tris-EDTA buffer (0.01 M Tris HCI + 1.5 mM EDTA, pH 7.4). Cytosol (4 ml) from hepatoma was incubated with 2 nM [3H]E z for 2 h before chromatography. A 400-MI aliquot was removed from each 2.5-ml fraction to determine the (3HIE2 content. Cytosol from normal male liver was chromatographed and [lH]E2 binding activity was detected after chromatography by incubating 200 MI of each fraction with 5 nM [3HIE2 for 2 h as described previously (12) . The column (2.4 x 45 cm) was previously calibrated with blue dextran, BSA, ovalbumin, trypsinogen. and myoglobin and the molecular weights of the [3H1E2 binding proteins were estimated (27) . In other studies on hepatoma, unlabeled cytosol was chromatographed and the [3H1E2 binding activity in each fraction was detected as described previously with unbound steroid being removed by dextran-charcoal treatment (12) .
Immunoprecipitation Studies
Protein A-Sepharose was washed and coupled according to the manufacturer's recommendations to either rabbit antibodies against mouse a-fetoprotein (anti-AFP), or to goat antibodies against rabbit immunoglobulin G, the latter being used as a control preparation. Each preparation was stored as a slurry in TED buffer, 1 volume resin to 7 volumes buffer. Serum from normal and hepatomabearing animals, cytosol from normal male rat liver, liver of tumor-bearing hosts, and hepatoma were tested for estrogen binding activity by incubating aliquots (200 MI) of each with 5 nM [3H)E2 for 2 h at DoC. Unbound steroid was removed with dextran-coated charcoal (12) . Serum from host animals and hepatoma cytosol were diluted until 
Auxiliary Methods
Protein concentration of cytosol was determined by the method of Lowry (28) using BSA as a standard. Radioactivity content of samples was determined in a Packard Tri-carb liquid scintillation spectrometer (Packard Instrument Co., Inc., Downers Grove, Ill.) Multiple results were expressed as mean ± SD and statistical analysis was performed using Student's nonpaired t-test.
Results
A typical binding curve obtained using the protamine sulfate technique for isolating cytoplasmic estradiol receptors from normal adult male rat liver is shown in Figure 1 . Binding is saturable and of limited capacity. Figure 2 demonstrates a plot of the specific binding data using the method of Scatchard for analysis. A single class of binding (receptor) molecules for estradiol with a uniform affinity was found (r = 0.99). In this particular experiment, the binding capacity was determined to be 35.8 fmol E2/mg protein and the Kd was determined to be 4.42 x 10-10 M. Next, the level of estrogen receptors was assessed in several normal livers and in hepatoma tissue as described in Figures 1 and 2 . Figure 3 shows the specific binding of normal male rat liver (six samples) and that of Morris hepatoma 7777 (six samples). In four of the hepatomas the estrogen receptors were not found, that is, no specific binding was detectable. Two other hepatomas contained small amounts of estrogen receptor (0.26 and 2.2 fmol/mg protein), much less than that detected in the normal liver. Other samples of hepatoma cytosol have been tested for retention on heparin-Sepharose, an affinity resin for steroid receptors; no estrogen binding activity was retained by this resin. To establish that the binding of the labeled estrogen in these studies was specific, the ability of various unlabeled steroids to compete with labeled estradiol was determined. The data shown in Figure  4 demonstrate that the binding was specific for estrogens. Thus. [3H]E2 binding was not inhibited by testosterone. DHT. and progesterone. While protamine sulfate precipitation of hepatoma cytosol resulted in the detection of little or no estrogen receptor. estrogen binding studies in whole hepatoma cytosol revealed the presence of a highcapacity estrogen binder. Binding studies show that this protein has a Kd for E2 of 5 x 10-8 M, indicating moderate affinity, and has a very high E2 binding capacity, 20 pmollmg cytosol protein (data not shown).
When whole cytosol from normal liver and hepatoma were tested for estrogen binder content using gel filtration chromatography, the results were strikingly different for these two tissues. As shown in Figure 5 , normal rat liver has two [3H]E2 binding species. The first, eluting in the void volume of the column, has been characterized extensively as the hepatic estrogen receptor (12) . The second, eluting from the column at a position consistent with a molecular weight of 25,000 is the hepatic male specific estrogen binder (MEB) described previously (12) . Protamine sulfate precipitates the receptor but not the MEB (12) . In contrast, the hepatoma contains neither the receptor nor the MEB, but instead contains a unique estrogen binder which elutes as a species of -70,000 molecular weight. Further analysis of this material pooled from fractions [34] [35] [36] after Sephadex G-100 chromatography reveals that unla- Figure 6 ). Diethylstilbesterol. however. is very effective in competing for [3H]E2 binding to the receptor of normal liver as shown in Figure 4 . suggesting that the protein which is present in hepatoma cytosol is not an altered form of the receptor. In addition. the specificity of the hepatoma estrogen binder differs from the MEB in that neither E3 nor 2-0Me-E2 competes for [3H]E2 binding to the hepatoma protein; both of these substances are avid competitors of [3H]E2 binding to MEB (12. manuscript in preparation). Furthermore, while protamine sulfate effectively precipitates the receptor of normal liver. it does not precipitate this hepatoma estrogen binder ( Figure 6) .
A protein known to bind estrogen with similar affinity and specificity. and of a molecular size similar to the estrogen binder in hepatoma is afetoprotein (AFP) (29) . Therefore. we treated cytosol from normal and host liver as well as from hepatoma with antiserum to AFP; the results are shown in Table 1 . Treatment of hepatoma cytosol with anti-AFP results in removal of most of the estrogen binding activity (82.4%). whereas control antiserum had no effect. Undiluted host liver cytosol contains some immunoprecipitable E2 binding activity. probably as a result of serum contamination, as the serum of the host animal contains large quantities of AFP activity. Normal rat liver cytosol, undiluted, or at a 
Discussion
The tumor-inducing potential of hormones in endocrine-related organs of experimental animals has been well demonstrated. Ever since Eisenfeld et GASTROENTEROLOGY Vol. 86. No. 6 a1. (5, 11) initially reported the presence of specific estradiol binding sites in the hepatic cytosol of adult female and male rats, and the subsequent demonstration of the presence of a molecule described as an androgen receptor in the same tissue by Milin et a1. (30) . many research teams (31) (32) (33) (34) have attempted to determine the relationship between hepatic steroid binding and the development of benign and malignant hepatic neoplasms.
In 1973, Baum et a1. (13) suggested a relationship between benign hepatic tumors and focal nodular hyperplasia and estrogen use in women who had a history of prior oral contraceptive use. In contrast to the usual relatively benign nature of contraceptive-(estrogenic) induced tumors, liver tumors associated with the use of anabolic steroids are usually malignant, especially when the androgen content of the hormonal preparation is high (35) (36) (37) .
At the present time, anabolic. androgenic, and estrogenic hormones are used widely for a variety of clinical indications. Because of this widespread use, numerous experiments have been performed to define the role of steroids, especially estrogens, in the pathogenesis of liver cell tumors. As a result of such studies, some authors have suggested that estrogens are carcinogenic (31, 33, 34) . For example, in animals given various preparations of estrogens and progestational agents, the liver tumor occurrence rate can be varied from 0% to 60% depending on the dose, agents given, and the time of exposure (34) .
Other authors have suggested that estrogens promote the carcinogenic effects of various procarcinogens but that they alone are not intrinsically carcinogenic (38) (39) (40) (41) . With such a hypothesis in mind. Wanless et al. (42) recently studied the diethylnitrosamine-pretreated rat model. In these experiments it was shown that estrogens promote the development of hepatic neoplasm by a mechanism which involves increasing the mitogenic activity of the hepatocyte nucleus. It should be noted, however, that the dosage of estrogen used in these experiments was ZOO-fold greater than that used clinically.
On the other hand, the biological importance of the estrogens in the process of malignant transformation of hepatic tumors has been questioned by Mishkin et al. (43) . These authors show that administration of estrogen and tamoxifen in combination results in a reversal of acetylaminofluorine-induced hepatic hypertrophy, nodular proliferation, and malignant transformation. These chemically induced nodules before estrogen treatment displayed decreased estrogen receptor levels as compared with normal liver; however, the effects of the subsequent estrogen treatment on receptor levels were not elucidated. It is generally conceded that hormone receptors are necessary for the maintenance of hormone dependency. At this time, however we are uncertain as to which factors control receptor levels, and further, what role these receptors play in the disease process.
Therefore, it may be premature to explain the relationship, if one exists, between the estrogen binding capacity of normal liver and experimental tumor or experimental estrogen-induced tumors. It is possible that the estrogen receptor is essential for participation in the early events of tumor formation, but that in later stages the estrogen, through its receptor, no longer exerts an influence on the cell. The present study clearly establishes that the Morris hepatic tumor does not have an increased estrogen receptor capacity or increased affinity for estrogens compared with normal rat liver. In contrast. the data clearly document reduced (p < 0.001) or no receptor binding activity by the tumor as compared with normal tissues. The lack of receptors in the transplantable Morris hepatoma 7777 may represent an endpoint of dedifferentiation in this tissue. In fact, estrogen receptors have been detected in human adenoma. but at a level significantly lower than in normal tissue from the same liver (44) . Further studies are necessary to confirm such a temporal relationship.
The estrogen binder that is present in hepatoma cytosol but not in protamine sulfate precipitates or normal liver is interesting. This estrogen binder has properties that suggested that it may be AFP. Its molecular weight is comparable to AFP (45, 46) and its specificity is such that DES does not compete for E2 binding, unlike the classic estrogen receptor (47) . We have confirmed its identity by its selective immunoprecipitation by antiserum to AFP. These studies, however. also point to a necessary caution; estrogen binding in unfractionated liver cytosol, particularly in abnormal tissue, does not necessarily indicate the presence of an estrogen receptor. It is essential to establish the presence of receptor by criteria other than simply its ability to bind estrogen.
